Dr. Jabbour on the Rationale to Evaluate KO-539 in Relapsed/Refractory AML
Elias Jabbour, MD, discusses the rationale to evaluate KO-539 in relapsed/refractory acute myeloid leukemia.
Dr. Olin on the Rationale to Evaluate Menin Inhibitors in AML
Rebecca L. Olin, MD, MSCE, discusses the rationale to evaluate menin inhibitors in acute myeloid leukemia.
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512